The STR profile of this cell line matches that of its parental cell line ATCC® Catalog No. CCL-185a. A549 is a human lung carcinoma cell line isolated in 1972 from a lung tumor of a male patient suffering from carcinoma.
Application
This product is a human A549 adenocarcinoma cell line in which a landing pad cassette has been integrated into the AAVS1 safe harbor locus using CompoZr®Zinc Finger Nuclease technology. The mKATE2 fluorescence gene was integrated following the EF1a promoter and flanked by unique Cre-lox sites. The design of this landing pad cassette allows for easy, fast, and affordable genetic modification using Cre recombinase. mKATE2 can easily be exchanged for a payload of the user′s choice using Cre recombinase and a targeting vector with appropriate lox sites. Cells can then be sorted via fluorescence-activated cell sorting (FACS) for loss of mKATE2 expression as a surrogate for successful integration of the targeting vector. Approximately 7-10 days are required for loss of the mKATE2 signal in successfully targeted cells. See technical bulletin for detailed protocols.
Biochem/physiol Actions
These cells are a human lung carcinoma cell line isolated from a lung tumor of a 58-year old male suffering from carcinoma. The cells possess a hypotriploid karyotype and express EGFR and mutant KRAS.
Features and Benefits
These cells contain the mKATE2 fluorescence gene flanked by unique Cre-lox sites inserted in the AAVS1 safe harbor gene. These A549 cells are adherent with a doubling time of approximately 22 hours.
Preparation Note
RPMI modified to contain 2mM L-glutamine, 10mM HEPES, 1mM sodium pyruvate, and 1500mg/L sodium bicarbonate. Add 10% FBS(Catalog Number F2442).
Analysis Note
Tested for Mycoplasma, bacterial and fungal content, post-freeze viability, short terminal repeat (STR) analysis for cell line identification.
Legal Information
ATCC is a registered trademark of American Type Culture Collection
CompoZr is a registered trademark of Merck KGaA, Darmstadt, Germany
